Gilead Stock News

These dividend stocks, including SCCO stock and CQP stock, offer high yields, a proven track record and high ratings in Dividend Grader. The post The 7 Highest Dividend Stocks for Income Investors app

Diamond Hill Capital (Trades, Portfolio) recently disclosed its 13F portfolio updates for the fourth quarter of 2021, which ended on Dec. 31.

– Industry veterans from Loxo/Lilly, Gilead, Seagen and AltruBio join Rain to expand clinical and regulatory operations – – In addition, Rain announces Advisory role to the CEO and Leadership team of John Maraganore, Ph.D., a position held since March 2021 – NEWARK, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NASDAQ: RAIN ), ("Rain") today announced the appointments of several industry veterans to the leadership team, including: Nora Ku, MD, Vice President of Clinical Development, joining from Loxo Oncology at Lilly Buenaflor (Flor) Nicolas, MPH, Vice President, Head of Global Drug Safety and Pharmacovigilance, joining from Gilead Sciences, Inc. Tina Kim-Hafken, MS, Vice President and Head of Global Regulatory Affairs, joining from Seagen Inc. Steve Flint, SHRM, MBA, Vice President of People & Culture, joining from AltruBio Inc. Additionally, Rain announced that John Maraganore, Ph.D., former founding CEO of Alnylam and biotechnology industry veteran, has served as a Special Advisor to Rain''s Chief Executive Officer (CEO), Avanish Vellanki, and the leadership team since March 2021. "We are excited to welcome these new members of the Rain leadership team, as we prepare for late-stage clinical and regulatory execution," said Avanish Vellanki, co-founder and CEO of Rain. "Further, Rain is pleased to have John Maraganore''s continued support as an advisor to me and the Rain leadership team.

The lucrative, new market could be tempered in 2022.

Gilead Sciences has seen a reasonable 2021, but 2022 outlook is a bit of a shock. Valuations are still reasonable, but after so many disappointments, GILD has something real to prove.

Gilead Sciences has seen a reasonable 2021, but the outlook for 2022 is a bit of a shock.

Gilead Sciences, Inc. (NASDAQ: GILD) shares remain under pressure even though the company reported strong fourth-quarter results last trading week. Gilead has increased quarterly dividend Gilead Scien

These companies' share prices could rise in the short term, but their long-term opportunities are even better.

To Our Shareholders

Gilead released FY21 earnings on Feb. 1 - revenues grew by 11% to $27bn and the P/E ratio was ~9x - likely to be best in the big Pharma sector. FY22 guidance is for a fall in revenues, but COVID thera

Joe Biden is redoubling his efforts to fight cancer with a new "cancer cabinet." Here are the biotech stocks to buy that can benefit.

Gilead's success could be inversely proportional to Pfizer's success with its COVID-19 pill.

Gilead's success could be inversely proportional to Pfizer's success with its COVID-19 pill.

Stocks that traded heavily or had substantial price changes Wednesday: Alphabet, Brinker International rise; PayPal, Gilead fall